Can molotinib/mometinib be used together?

Janus kinases (JAKs) are well-described signaling kinases that contain four family members, JAK1, JAK2, JAK3, and TYK2, which are required in hematological malignancies, as JAK mutations have been shown to contribute to the pathogenesis of myeloproliferative diseases. Momelotinib is a potent JAK1/JAK2 inhibitor effective in patients with primary and secondary myelofibrosis.

The purpose of combined medication is to use drugs with different mechanisms to act synergistically in order to improve efficacy, reduce side effects or overcome drug resistance. In the treatment of malignant tumors, it is often difficult to completely control the disease with a single drug, so researchers are actively exploring the possibility of combined drugs. For molotinib, since its mechanism of action is mainly through inhibiting the JAK-STAT signaling pathway, its combination with other targeted therapies or immunotherapy drugs is expected to produce better clinical effects.

HDAC6 has been reported to be overexpressed in lymphocytes, and its inhibition has shown activity in preclinical and clinical studies of lymphoproliferative diseases. Citarinostat is a second-generation HDAC6 selective inhibitor that is a well-tolerated compound with reduced potency against class I HDACs but retains anticancer efficacy compared with non-selective HDAC inhibitors. Both drugs are currently being studied in clinical trials, show favorable toxicity profiles, and are both available orally.

The results showed that after 24 hours, the combination of molotinib (1 μM) and Citarinostat (4 μM) had a better CI value. WSU-NHL, RL, Karpas422, Jeko1, Hut78, Karpas299, L540, RPMI8226 and U266 cells with <1 showed synergistic effects, while L1236, Granta519 and Mec1 cells with CI values >1 showed antagonistic effects. The drug combination exhibited strong cytotoxicity, manifested by reduced mitochondrial depolarization, depletion of ATP and lactate levels, and release of Cyt-C from mitochondria, but also by increased apoptotic index and reactive oxygen species levels, leading to cell cycle arrest in the sub-G0/G1 phase.

However, combining medications is not without risks. Drug interactions may exist between different drugs, resulting in increased side effects or decreased efficacy. Therefore, when designing a combination regimen, careful assessment of the patient's overall condition, previous medication history, and possible drug interactions is required. In addition, the results of clinical trials are also crucial, and researchers need to verify the safety and effectiveness of combination drugs in large randomized controlled trials.

In recent years, several clinical trials are evaluating the use of molotinib in combination with other drugs, for example, in combination with chemotherapy, targeted drugs, or immunotherapy. These studies will provide data support for clinical practice and help doctors develop more personalized treatment strategies. Due to favorable toxicity and oral administration, combination therapy with molotinib andCitarinostat may represent a promising new therapy for the treatment of hematological malignancies. This research is ongoing and requires further investigation.